141 related articles for article (PubMed ID: 11809685)
1. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
[TBL] [Abstract][Full Text] [Related]
2. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
4. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
5. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
6. Preparation and application of antibodies to phosphoamino acid sequences.
Sun T; Campbell M; Gordon W; Arlinghaus RB
Biopolymers; 2001; 60(1):61-75. PubMed ID: 11376433
[TBL] [Abstract][Full Text] [Related]
7. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
8. Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Wang Y; Liu J; Wu Y; Luo W; Lin SH; Lin H; Hawk N; Sun T; Guo JQ; Estrov Z; Talpaz M; Champlin R; Arlinghaus RB
Cancer Res; 2001 Jan; 61(1):138-44. PubMed ID: 11196151
[TBL] [Abstract][Full Text] [Related]
9. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON
Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
Oda T; Kujovich J; Reis M; Newman B; Druker BJ
Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
12. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
[TBL] [Abstract][Full Text] [Related]
13. Bcr phosphorylated on tyrosine 177 binds Grb2.
Ma G; Lu D; Wu Y; Liu J; Arlinghaus RB
Oncogene; 1997 May; 14(19):2367-72. PubMed ID: 9178913
[TBL] [Abstract][Full Text] [Related]
14. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
Nieborowska-Skorska M; Slupianek A; Skorski T
Oncogene; 2000 Aug; 19(36):4117-24. PubMed ID: 10962572
[TBL] [Abstract][Full Text] [Related]
15. BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
Lin F; Monaco G; Sun T; Liu J; Lin H; Stephens C; Belmont J; Arlinghaus RB
Oncogene; 2001 Apr; 20(15):1873-81. PubMed ID: 11313935
[TBL] [Abstract][Full Text] [Related]
16. A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction.
Muller AJ; Pendergast AM; Havlik MH; Puil L; Pawson T; Witte ON
Mol Cell Biol; 1992 Nov; 12(11):5087-93. PubMed ID: 1383690
[TBL] [Abstract][Full Text] [Related]
17. Exon-skipping in BCR/ABL is induced by ABL exon 2.
Lichty BD; Kamel-Reid S
Biochem J; 2000 May; 348 Pt 1(Pt 1):63-9. PubMed ID: 10794714
[TBL] [Abstract][Full Text] [Related]
18. Specific binding of Fyn and phosphatidylinositol 3-kinase to the B cell surface glycoprotein CD19 through their src homology 2 domains.
Chalupny NJ; Aruffo A; Esselstyn JM; Chan PY; Bajorath J; Blake J; Gilliland LK; Ledbetter JA; Tepper MA
Eur J Immunol; 1995 Oct; 25(10):2978-84. PubMed ID: 7589101
[TBL] [Abstract][Full Text] [Related]
19. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
20. p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
Korus M; Mahon GM; Cheng L; Whitehead IP
Oncogene; 2002 Jul; 21(30):4601-12. PubMed ID: 12096337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
